Searching for therapeutic synergy in primary effusion lymphoma

Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies.

In this issue of the Journal of Clinical Investigation, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat and cutaneous , respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors.

These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.

More information: Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma, J Clin Invest. doi:10.1172/JCI64503

add to favorites email to friend print save as pdf

Related Stories

Scientists tackle viral mysteries

Jun 29, 2009

Scientists know that some cancers are triggered by viruses, which take over cellular systems and cause uncontrolled cell growth. Doctors - and patients who get shingles late in life - have also known for many years that ...

Recommended for you

Incomplete HPV vaccination may offer some protection

36 minutes ago

Minority women who received the Human Papillomavirus Vaccination (HPV) even after becoming sexually active had lower rates of abnormal Pap test results than those who were never vaccinated. These findings appear in the journal ...

New imaging agent provides better picture of the gut

41 minutes ago

A multi-institutional team of researchers has developed a new nanoscale agent for imaging the gastrointestinal (GI) tract. This safe, noninvasive method for assessing the function and properties of the GI tract in real time ...

User comments